Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "THOR Study - Erdafitinib vs. Pembrolizumab in Pretreated Patients With Advanced/Metastatic Urothelial Cancer With Select FGFR Alterations"
Login to view comments.
Click here to Login
Genitourinary